Morishima Satoko

写真a

Researcher Number(JSPS Kakenhi)

40463195

Current Affiliation Organization 【 display / non-display

  • Duty   University of the Ryukyus   Graduate School of Medicine  

Research Areas 【 display / non-display

  • Life Science / Hematology and medical oncology

Published Papers 【 display / non-display

  • A Comprehensive Study of the Immunophenotype and its Clinicopathologic Significance in Adult T-Cell Leukemia/Lymphoma.

    Tamaki T, Karube K, Sakihama S, Tsuruta Y, Awazawa R, Hayashi M, Nakada N, Matsumoto H, Yagi N, Ohshiro K, Nakazato I, Kitamura S, Nishi Y, Miyagi T, Yamaguchi S, Nakachi S, Morishima S, Masuzaki H, Takahashi K, Fukushima T, Wada N

    Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc   36 ( 8 ) 100169   2023.03 [ Peer Review Accepted ]

    Type of publication: Research paper (scientific journal)

  • An open-label, single-arm phase 2 trial of valemetostat for relapsed or refractory adult T-cell leukemia/lymphoma.

    Izutsu K, Makita S, Nosaka K, Yoshimitsu M, Utsunomiya A, Kusumoto S, Morishima S, Tsukasaki K, Kawamata T, Ono T, Rai S, Katsuya H, Ishikawa J, Yamada H, Kato K, Tachibana M, Kakurai Y, Adachi N, Tobinai K, Yonekura K, Ishitsuka K

    Blood ( Blood )  141 ( 10 ) 1159 - 1168   2023.03 [ Peer Review Accepted ]

    Type of publication: Research paper (scientific journal)

     View Summary

    Adult T-cell leukemia/lymphoma (ATL) is an aggressive non-Hodgkin lymphoma with poor prognosis and few treatment options for patients with relapsed, recurrent, or refractory disease. We evaluated the efficacy and safety of valemetostat, a potent EZH1 and EZH2 inhibitor, in treating relapsed/refractory (R/R) ATL. This multicenter phase 2 trial (NCT04102150; https://clinicaltrials.gov/ct2/show/NCT04102150; DS3201-A-J201) enrolled patients with R/R aggressive ATL (acute, lymphoma, unfavorable chronic type). Patients received valemetostat 200 mg/day until progressive disease or unacceptable toxicity. The primary endpoint was overall response rate (ORR) centrally assessed by an independent efficacy assessment committee (IEAC). Secondary endpoints included best response in disease compartments, duration of response (DOR), pharmacokinetics, and safety. Twenty-five patients (median age, 69.0) with a median of 3 prior lines of therapy were enrolled; 24 had prior mogamulizumab treatment. The primary endpoint was met with a centrally reviewed ORR of 48.0% (90% CI, 30.5% to 65.9%), including 5 complete and 7 partial remissions. Patients pretreated with mogamulizumab had an ORR of 45.8% (4 complete and 7 partial remissions). IEAC-assessed median DOR was not reached (NR; 95% CI, 1.87 months to NR). Treatment-emergent adverse events (TEAEs) were manageable. TEAEs that occurred in ≥20% of patients included thrombocytopenia, anemia, alopecia, dysgeusia, neutropenia, lymphopenia, leukopenia, decreased appetite, and pyrexia. Grade ≥3 TEAEs included thrombocytopenia, anemia, lymphopenia, leukopenia, and neutropenia. Valemetostat demonstrated promising efficacy and tolerability in heavily pretreated patients, warranting further investigation in treating R/R ATL.

  • Effect of Multiple HLA Locus Mismatches on Outcomes after Single Cord Blood Transplantation.

    Kanda J, Hirabayashi S, Yokoyama H, Kawase T, Tanaka H, Uchida N, Taniguchi S, Takahashi S, Onizuka M, Tanaka M, Sugio Y, Eto T, Kanda Y, Kimura T, Ichinohe T, Atsuta Y, Morishima S, Japanese Society for Transplantation and Cellular Therapy's HLA Working Group

    Transplantation and cellular therapy ( Transplantation and Cellular Therapy )  28 ( 7 ) 398.e1 - 398.e9   2022.07 [ Peer Review Accepted ]

    Type of publication: Research paper (scientific journal)

     View Summary

    BACKGROUND: Effect of single or multiple mismatches at each HLA locus on outcomes after cord blood transplantation (CBT) is controversial. OBJECTIVE: We analyzed the effects of single or multiple HLA-locus mismatches on the outcomes after single CBT using a Japanese registry data from the Japan Society for Hematopoietic Cell Transplantation (JSHCT). STUDY DESIGN: Patients with acute leukemia and myelodysplastic syndromes, aged 16 years or older, who underwent their first CBT between 2003 and 2017 (n = 4,074) were included. The effect of the number of HLA-locus mismatches (0, 1, and 2, for the HLA-A, -B, -C, and -DRB1 loci) on outcomes was analyzed after adjusting for other significant variables. RESULTS: The median age of the patients was 54 years. Median total nucleated and CD34 cell doses were 2.6 × 107/kg and 0.8 × 105/kg, respectively. The number of CBTs with single or double mismatches were 2,099 and 292 for HLA-A locus, 2,699 and 341 for HLA-B locus, 2,555 and 609 for HLA-C locus, and 2,593 and 571 for HLA-DRB1 locus, respectively. Single and double HLA-DRB1 mismatches were associated with a higher risk of grade II-IV acute graft-versus-host disease (GVHD, single: HR 1.29, P<0.001, double: HR 1.49, P<0.001, trend-P: P<0.001). Single and double mismatches at HLA-DRB1 as well as single mismatches at HLA-A and HLA-B were also associated with grade III-IV acute GVHD. Single and double HLA-B mismatches and double HLA-DRB1 mismatches were associated with a high risk of non-relapse mortality. On the other hand, double mismatches at HLA-A or HLA-DRB1 and single mismatches at HLA-B were associated with a lower risk of relapse. CONCLUSION: HLA-DRB1 double mismatch was associated with high risks of grade II-IV and III-IV acute GVHD and non-relapse mortality but lower risk of relapse. Not only the locus mismatch but also the number of mismatches may be considered in cord blood unit selection.

  • Decision Analysis for Unrelated Bone Marrow Transplantation or Immediate Cord Blood Transplantation for Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia in First Complete Remission.

    Shinichi Kako, Fumihiko Hayakawa, Koichi Miyamura, Junji Tanaka, Kiyotoshi Imai, Junya Kanda, Satoko Morishima, Naoyuki Uchida, Noriko Doki, Kazuhiro Ikegame, Yukiyasu Ozawa, Satoru Takada, Noriko Usui, Shigeki Ohtake, Hitoshi Kiyoi, Itaru Matsumura, Yasushi Miyazaki, Tatsuo Ichinohe, Takahiro Fukuda, Yoshiko Atsuta, Yoshinobu Kanda

    Transplantation and cellular therapy   28 ( 3 ) 161.e1-161.e10   2022.03 [ Peer Review Accepted ]

    Type of publication: Research paper (scientific journal)

     View Summary

    An HLA-matched relative is the first-choice donor for patients with Philadelphia chromosome (Ph)-negative acute lymphoblastic leukemia (ALL) in first complete remission (CR1). The most promising alternative donor is thought to be an HLA-matched unrelated donor (MUD) in patients who do not have an HLA-matched related donor. Cord blood transplantation (CBT) is an alternative option. Higher rates of engraftment failure and nonrelapse mortality (NRM) are significant problems, but the ready availability of cord blood can be an advantage, because patients can immediately undergo transplantation before progression. This study was conducted to identify an appropriate alternative donor in patients with Ph-negative ALL in CR1 who do not have an HLA-matched related donor (MRD). Decision analyses using a Markov model were performed to compare immediate CBT, in which CBT was performed at 1 month after the achievement of CR1, with elective unrelated bone marrow transplantation (uBMT) from an 8/8 MUD (8/8 uBMT) or uBMT from a 7/8 MUD (7/8 uBMT), in which uBMT was performed at 4 months, in patients age 16 to 55 years with Ph-negative ALL in CR1 who did not have an MRD. We constructed a decision tree. The cycle length was set at 3 months, and analyses were performed for 19 cycles for uBMT and 20 cycles for CBT, resulting in evaluation of the 5-year life expectancy after both decisions. Transition probabilities (TPs) and utilities were estimated from prospective and retrospective Japanese studies and the registry database of Japan. Subgroup analyses were performed according to risk stratification based on WBC count and cytogenetics at diagnosis and according to age stratification, with a cutoff of 25 years. One-way sensitivity analyses for TPs and utilities were performed as well. The baseline analyses showed that 8/8 uBMT or 7/8 uBMT had superior results to CBT, with quality-adjusted life years (QALYs) of 2.86 in 8/8 uBMT, 2.84 in 7/8 uBMT, and 2.75 in CBT. One-way sensitivity analyses showed that the results of the baseline analyses were reversed if the probability of NRM in CBT improved. Subgroup analyses showed similar results in younger, older, and high-risk patients. However, QALY was worse in 8/8 uBMT compared with CBT in standard-risk patients. In one-way sensitivity analyses, the probabilities of NRM in uBMT and CBT affected the baseline results in all analyses except for comparisons between 8/8 uBMT and CBT in younger and high-risk patients. In these 2 populations, the superiority of 8/8 uBMT was consistently demonstrated throughout the one-way sensitivity analyses. For patients with Ph-negative ALL in CR1 who decide to undergo transplantation from an alternative donor, elective uBMT from either an 8/8 MUD or a 7/8 MUD is expected to yield a better outcome than immediate CBT. Nonetheless, CBT is a viable option, and improvements to reduce the risk of NRM in CBT may change these results.

  • Impact of HLA Epitope Matching on Outcomes After Unrelated Bone Marrow Transplantation.

    Iwasaki M, Kanda J, Tanaka H, Shindo T, Sato T, Doki N, Fukuda T, Ozawa Y, Eto T, Uchida N, Katayama Y, Kataoka K, Ara T, Ota S, Onizuka M, Kanda Y, Ichinohe T, Atsuta Y, Morishima S

    Frontiers in immunology ( Frontiers in Immunology )  13   811733   2022 [ Peer Review Accepted ]

    Type of publication: Research paper (scientific journal)

     View Summary

    The significance of antibody-identified epitopes stimulating humoral alloimmunity is not well understood in the identification of non-permissive human leukocyte antigen (HLA) mismatching patterns in hematopoietic stem cell transplantation (HSCT). This was a retrospective study in a cohort of 9,991 patients who underwent their first HSCT for hematologic malignancies from unrelated bone marrow donors in the Transplant Registry Unified Management Program (TRUMP). HLA eplet mismatches (EMM) were quantified using HLAMatchmaker (HLAMM). The median age of patients was 48 years (range, 16 to 77). The number of EMM in recipient-donor pairs in our study population ranged from 0 to 37 in HLA class I (median, 0) and 0 to 60 in HLA class II (median, 1). In addition to the known high-risk mismatch patterns in the Japanese cohort, HLA-C EMM in the GVH direction was associated with a significantly higher risk for grade III-IV aGVHD, leading to a higher risk of non-relapse mortality and lower overall survival (compared with HLA-C matched patients, HR 1.67, 95% CI 1.44–1.95; HR 1.39, 95% CI 1.25–1.54; HR 1.20, 95% CI 1.10–1.30, respectively). HLAMM-based epitope matching might be useful for identifying patients who are at high risk for serious complications after HSCT from HLA mismatched unrelated donors.

display all >>

Grant-in-Aid for Scientific Research 【 display / non-display

  • Grant-in-Aid for Scientific Research(C)

    Project Year: 2020.04  -   

    Direct: 3,300,000 (YEN)  Overheads: 990,000 (YEN)  Total: 4,290,000 (YEN)

  • Grant-in-Aid for Scientific Research on Innovative Areas

    Project Year: 2019.04  -   

    Direct: 6,000,000 (YEN)  Overheads: 1,800,000 (YEN)  Total: 7,800,000 (YEN)

  • Grant-in-Aid for Scientific Research(C)

    Project Year: 2017.04  -  2020.03 

    Direct: 3,500,000 (YEN)  Overheads: 1,050,000 (YEN)  Total: 4,550,000 (YEN)

  • Grant-in-Aid for Scientific Research on Innovative Areas

    Project Year: 2017.04  -  2019.03 

    Direct: 6,000,000 (YEN)  Overheads: 1,800,000 (YEN)  Total: 7,800,000 (YEN)

  • Grant-in-Aid for Scientific Research(C)

    Project Year: 2014.04  -  2017.03 

    Direct: 3,800,000 (YEN)  Overheads: 1,140,000 (YEN)  Total: 4,940,000 (YEN)